Advancing the randomized Phase 1 trial of TG4070 could broaden its clinical opportunity in NSCLC, with five French sites actively recruiting and topline results from TG4050's Phase 2 trial expected by the end of Q1 2028.

Merck and Moderna's INTerpath program comprises nine trials. Spanning Phase 2 and Phase 3, it includes three ongoing Phase 3 NSCLC trials.

Transgene's vaccine case hinges on confirming the TG4050 Phase 2 signal and manufacturing readiness, while a rival vaccine's Phase 3 progress makes competition material. In Phase I, none of 16 evaluable patients in the immediate-treatment arm relapsed after a median 30-month follow-up, while 3 of 16 in the control arm relapsed, and Phase 2 topline results are expected by end-Q1 2028. Intismeran plus KEYTRUDA reduced recurrence or death risk 42% versus KEYTRUDA alone in completely resected stage IIB-IV melanoma.

Transgene said it remained on track to have Phase 3-ready manufacturing capacity by the end of 2027.

Transgene's main execution risk is that TG4050's expected Phase 2 results and its planned Phase 3 transition coincide with cash that, under its current plans, provides financial visibility only until early 2028. The company expected to communicate topline results from TG4050's Phase 2 trial by the end of Q1 2028, and was preparing a potential Phase 3 trial following the Phase 2 study's two-year disease-free-survival results expected in Q1 2028.

Transgene said it was on track to have Phase 3-ready manufacturing capacity by the end of 2027.

The myvac platform links patient-specific neoantigen selection and vector design with individualized, on-demand treatment production: it selects tumor-specific neoantigens using artificial intelligence, integrates the selected neoantigens into the genome of its MVA viral vector through VacDesignR, and produces each treatment for each patient in an in-house unit that complies with GMP standards.

The immunotherapies from this platform produce T cells directed at malignant cells.